Chondroprotective and anti-inflammatory effects of S-methylisothiourea, an inducible nitric oxide synthase inhibitor in cartilage and synovial explants model of osteoarthritis

Journal of Pharmacy and Pharmacology

Volumn 66, Issue 7, 2014, Pages 1021-1031

  Balaganur, Venkanna ^a   Pathak, Nitya Nand ^a   Lingaraju, Madhu Cholenahalli ^a   More, Amar Sunil ^a   Latief, Najeeb ^a   Kumari, Rashmi Rekha ^a   Kumar, Dinesh ^a   Tandan, Surendra K ^a  

^a INDIAN VETERINARY RESEARCH INSTITUTE   (India)

Author keywords

cartilage explants; osteoarthritis; S methylisothiourea; synovial explants

Indexed keywords

COLLAGENASE 3; GLYCOSAMINOGLYCAN; HYDROXYPROLINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; LACTATE DEHYDROGENASE; NITRIC OXIDE SYNTHASE INHIBITOR; NITRITE; PROSTAGLANDIN E2; PROTEOGLYCAN; S METHYLPSEUDOTHIOUREA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; AUTACOID; CYTOKINE; ENZYME INHIBITOR; LIPOPOLYSACCHARIDE; S-METHYLISOTHIOPSEUDOURONIUM; THIOUREA DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARTILAGE; CELL VIABILITY; CHONDROPROTECTION; COLLAGEN DEGRADATION; CONTROLLED STUDY; CULTURE MEDIUM; CYTOTOXICITY; ENZYME RELEASE; EXPLANT; IN VITRO STUDY; MALE; NONHUMAN; OSTEOARTHRITIS; RABBIT; SYNOVITIS; SYNOVIUM; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTICULAR CARTILAGE; CARTILAGE CELL; DRUG EFFECTS; HUMAN; INFLAMMATION; METABOLISM; RAT; WISTAR RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CARTILAGE, ARTICULAR; CHONDROCYTES; CYTOKINES; ENZYME INHIBITORS; GLYCOSAMINOGLYCANS; HUMANS; HYDROXYPROLINE; IN VITRO TECHNIQUES; INFLAMMATION; INFLAMMATION MEDIATORS; ISOTHIURONIUM; LIPOPOLYSACCHARIDES; MALE; MATRIX METALLOPROTEINASE 13; NITRIC OXIDE SYNTHASE TYPE II; NITRITES; OSTEOARTHRITIS; RABBITS; RATS; RATS, WISTAR; SYNOVIAL MEMBRANE;

EID: 84902533543     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12228     Document Type: Article

References (56)

1. Lohmander LS,. What can we do about osteoarthritis? Arthritis Res 2000; 2: 95-100.
2. Stichtenoth DO, et al. Microsomal prostaglandin E synthase is regulated by proinflammatory cytokines and glucocorticoids in primary rheumatoid synovial cells. J Immunol 2001; 167: 469-474.
3. Kobayashi M, et al. Role of interleukin-1 and tumor necrosis factor alpha in matrix degradation of human osteoarthritic cartilage. Arthritis Rheum 2005; 52: 128-135.
4. McInnes IB, et al. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med 1996; 184: 1519-1524.
5. Stadler J, et al. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J Immunol 1991; 147: 3915-3920.
6. Palmer RM, et al. Induction of nitric oxide synthase in human chondrocytes. Biochem Biophys Res Commun 1993; 193: 398-405.
7. Hauselmann HJ, et al. Nitric oxide and proteoglycan biosynthesis by human articular chondrocytes in alginate culture. FEBS Lett 1994; 352: 361-364.
8. Cao M, et al. Nitric oxide inhibits the synthesis of type-II collagen without altering Col2A1 mRNA abundance: prolyl hydroxylase as a possible target. Biochem J 1997; 324: 305-310.
9. Stefanovic-Racic M, et al. The role of nitric oxide in proteoglycan turnover by bovine articular cartilage organ cultures. J Immunol 1996; 156: 1213-1220.
10. Stefanovic-Racic M, et al. Nitric oxide and proteoglycan turnover in rabbit articular cartilage. J Orthop Res 1997; 15: 442-449.
11. Bird JL, et al. Nitric oxide inhibits aggrecan degradation in explant cultures of equine articular cartilage. Equine Vet J 2000; 32: 133-139.
12. Bird JL, et al. IL-1β induces the degradation of equine articular cartilage by a mechanism that is not mediated by nitric oxide. Biochem Biophys Res Commun 1997; 238: 81-85.
13. Murrell GA, et al. Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995; 206: 15-21.
14. Tamura T, et al. Nitric oxide mediates interleukin-1-induced matrix degradation and basic fibroblast growth factor release in cultured rabbit articular chondrocytes: a possible mechanism of pathological neovascularization in arthritis. Endocrinol 1996; 137: 3729-3737.
15. Manfield L, et al. Nitric oxide enhances cyclooxygenase activity in articular cartilage. Inflamm Res 1996; 45: 254-258.
16. Takahashi K, et al. Effect of hyaluronan on chondrocyte apoptosis and nitric oxide production in experimentally induced osteoarthritis. J Rheumatol 2000; 27: 1713-1720.
17. Järvinen TAH, et al. Nitric oxide mediates interleukin-1 induced inhibition of glycosaminoglycan synthesis in rat articular cartilage. Mediat Inflamm 1995; 4: 107-111.
18. More AS, et al. Effect of iNOS inhibitor S-methylisothiourea in monosodium iodoacetate-induced osteoathritic pain: Implication for osteoarthritis therapy. Pharmacol Biochem Be 2013; 103: 764-772.
19. Pelletier JP, et al. Etiopathogenesis of osteoarthritis. In:, Koopman WJ, ed. A Textbook of Rheumatology. Arthritis and Allied Conditions. Baltimore, MD: Lippincott Williams & Wilkins, 2001: 1969-1984.
20. Pelletier JP, et al. Osteoarthritis, an inflammatory disease. Potential implication for the selection of new therapeutic targets. Arthritis Rheum 2001; 44: 1237-1247.
21. Saito I, et al. Increased cellular infiltrate in inflammatory synovial of osteoarthritic knees. Osteoarthr Cartilage 2002; 10: 156-162.
22. Sharif M, et al. Increased serum C reactive protein may reflect events that precede radiographic progression in osteoarthritis of the knee. Ann Rheum Dis 2000; 59: 71-74.
23. Sharif M, et al. Suggestion of nonlinear or phasic progression of knee osteoarthritis based on measurements of serum cartilage oligomeric matrix protein levels over five years. Arthritis Rheum 2004; 50: 2479-2488.
24. Nishimura M, et al. Relationship between pain-related mediators and both synovitis and join pain in patients with internal derangements and osteoarthritis of the temporomandibular joint. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002; 94: 328-332.
25. Trumble TN, et al. Correlation of prostaglandin E2 concentrations in synovial fluid with ground reaction forces and clinical variables for pain and inflammation in dogs with osteoarthritis induced by transection of the cranial cruciate ligament. Am J Vet Res 2004; 65: 1269-1275.
26. Csonge L, et al. Banking of osteochondral allografts. Part I. Viability assays adapted for osteochondrol and cartilage studies. Cell Tissue Bank 2002; 3: 151-159.
27. Farndale RW, et al. Improved quantitation and discrimination of sulphated glycosaminoglycans by use of dimethylmethylene blue. Biochim Biophys Acta 1986; 883: 173-177.
28. Reddy GK, et al. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 1996; 29: 225-229.
29. Green LC, et al. Analysis of nitrate, nitrite and 15N in biological fluids. Anal Biochem 1982; 126: 131-136.
30. Hyc A, et al. Preparation of rat synovial membrane for studies of cytokine secretion. Folia Histochem Cyto 2007; 45: 57-60.
31. Southan GJ, et al. Isothioureas: potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br J Pharmacol 1995; 114: 510-516.
32. Szabo C, et al. Beneficial effects and improved survival in rodent models of septic shock with S-methylisothiourea sulfate, a potent and selective inhibitor of inducible nitric oxide synthase. Proc Natl Acad Sci 1994; 91: 12472-12476.
33. Rosselet A, et al. Selective iNOS inhibition is superior to norepinephrine in the treatment of rat endotoxic shock. Am J Respir Crit Care Med 1998; 157: 162-170.
34. Southan GJ, Szabõ C,. Selective pharmacological inhibition of distinct nitric oxide synthase isoforms. Biochem Pharmacol 1996; 51: 383-394.
35. Stevens AL, et al. Nitric oxide enhances aggrecan degradation by aggrecanase in response to TNF-alpha but not IL-1beta treatment at a post-transcriptional level in bovine cartilage explants. Osteoarthr Cartilage 2008; 16: 489-497.
36. Cipolletta C, et al. Modulation of IL-1-induced cartilage injury by NO synthase inhibitors: a comparative study with rat chondrocytes and cartilage entities. Br J Pharmacol 1998; 124: 1719-1727.
37. Lin PM, et al. Increased stromelysin-1 (MMP-3), proteoglycan degradation (3B3- and 7D4) and collagen damage in cyclically load-injured articular cartilage. Osteoarthr Cartilage 2004; 12: 485-496.
38. Little CB, et al. Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation. Matrix Biol 2002; 21: 271-288.
39. Farrell AJ, et al. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 1992; 51: 1219-1222.
40. Melchiorri C, et al. Enhanced and coordinated in vivo expression of inflammatory cytokines and nitric oxide synthase by chondrocytes from patients with osteoarthritis. Arthritis Rheum 1998; 41: 2165-2174.
41. Scher JU, et al. Nitric oxide synthases and osteoarthritis. Curr Rheumatol Rep 2007; 9: 9-15.
42. Hashimoto S, et al. Chondrocyte apoptosis and nitric oxide production during experimentally induced osteoarthritis. Arthritis Rheum 1998; 41: 1266-1274.
43. Vuolteenaho K, et al. Leptin enhances synthesis of proinflammatory mediators in human osteoarthritic cartilage-mediator role of NO in leptin-induced PGE2, IL-6, and IL-8 production. Mediat Inflamm Article 2009; ID 345838: 1-10.
44. Attur M, et al. Prostaglandin E2 exerts catabolic effects in osteoarthritis cartilage: evidence for signaling via the EP4 receptor. J Immunol 2008; 181: 5082-5088.
45. Panico AM, et al. Protective effects of benzisothiazolylamidines on IL-1 beta induced alterations in human articular chondrocyte metabolism. Inflammation 2004; 28: 231-235.
46. Faour WH, et al. Prostaglandin E2 stimulates p53 transactivational activity through specific serine 15 phosphorylation in human synovial fibroblasts. Role in suppression of c/EBP/NF-kappaBmediated MEKK1-induced MMP-1 expression. J Biological Chem 2006; 281: 19849-19860.
47. Daheshia M, Yao JQ,. The interleukin 1beta pathway in the pathogenesis of osteoarthritis. J Rheumatol 2008; 35: 2306-2312.
48. Dodge GR, Poole AR,. Immunohistochemical detection and immunochemical analysis of type II collagen degradation in human normal, rheumatoid, and osteoarthritic articular cartilages and in explants of bovine articular cartilage cultured with interleukin 1. J Clin Invest 1989; 83: 647-661.
49. Martel-Pelletier J, et al. Metalloproteases and inhibitors in arthritic diseases. Baillieres Best Pract Res Clin Rheumatol 2001; 15: 805-829.
50. Clegg PD, et al. Matrix metalloproteinases 2 and 9 in equine synovial fluids. Equine Vet J 1997; 29: 343-348.
51. Benito MJ, et al. Synovial tissue inflammation in early and late osteoarthritis. Ann Rheum Dis 2005; 64: 1263-1267.
52. Kim SF, et al. Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science 2005; 310: 1966-1970.
53. Slomiany BL, et al. Role of constitutive nitric oxide synthase in regulation of Helicobacter pylori-induced gastric mucosal cyclooxygenase-2 activation through S-nitrosylation: mechanism of ghrelin action. Open J Gastroenterol 2011; 1: 13-22.
54. Briston L, et al. Age-related differences in prostaglandin E2 synthesis by equine cartilage explants and synoviocytes. J Vet Pharmacol Ther 2010; 33: 268-276.
55. Rollin R, et al. Early lymphocyte activation in the synovial microenvironment in patients with osteoarthritis: comparison with rheumatoid arthritis patients and healthy controls. Rheumatol Int 2008; 28: 757-764.
56. Beekhuizen M, et al. Osteoarthritic synovial tissue inhibition of proteoglycan production in human osteoarthritic knee cartilage: establishment and characterization of a long-term cartilage-synovium coculture. Arthritis Rheum 2011; 63: 1918-1927.